I

InflaRx NV
D

IFRX

0.88400
USD
-0.01
(-1.43%)
مفتوح الان
حجم التداول
1,450
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
59,345,812
أصول ذات صلة
A
AMRN
9.05260
(1,979.14%)
9.51000 USD
C
CRBP
0.17000
(2.98%)
5.87000 USD
M
MTNB
0.03830
(7.98%)
0.51830 USD
V
VKTX
-0.130
(-0.60%)
21.390 USD
المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.